exceptional service across specialties

The journey for patients with complex, hard-to-diagnose diseases can be long and challenging. Many spend years moving from one specialist to another before receiving a diagnosis, and managing treatment and related difficulties can be a daily struggle.

As a specialty pharmacy focused on supporting patients with these complex conditions, we are committed to guiding you through every stage of theat journey, both clinically and administratively to help you achieve the best possible outcomes. Out Therapy Care Teams are extensively trained in each condition we support, allowing us to tailor our approach to meet the unique needs of every patient. Learn more about the conditions and therapies we support below.

Asthma & Allergy

Asthma is a long term condition causing inflammation to the airways and making it difficult to breathe.

Bleeding Disorders

There are several bleeding disorders such as Hemophilia, Von Willebrand disease, and several clotting factors deficiencies.

Hepatitis B

Chronic Hepatitis B is a virus transmitted by bodily fluids that can lead to serious liver damage.

Hepatitis C

Hepatitis C is an infection caused by a bloodborne virus affecting the liver.

HIV

HIV is a serious viral infection that attacks the body’s immune system and if left untreated can seriously impair the body’s ability to fight off infections.

Inflammatory Bowel Disease

IBD is inflammation of the GI tract manifesting in either Crohn’s disease or Ulcerative colitis.

Multiple Sclerosis

MS is a very complex disease affecting the central nervous system.

Oncology

Oncology involves several different types of cancer and can affect multiple areas of the body.

Pulmonary Hypertension

PH is a rare condition in which high blood pressure occurs specifically in the lungs.

Rheumatology

Many rheumatologic diseases are autimmune conditions often times affecting the joints.

Sickle Cell Disease

Sickle cell disease is caused by a hereditary condition affecting the red blood cells.

Transplant

Transplant refers to the life-saving organ transplantation of a healthy organ to another individual.

Search by Drug

Search by Condition or Specialty

  • Inflectra

    • Drug: Inflectra (infliximab-dyyb)
    • Manufacturer: Pfizer
    • Route of Administration: Intravenous
    • Site of Care: Outpatient

    • Approved Indication:

        • reducing signs and symptoms and inducing and maintaining clinical remission in adults or pediatric patients 6 years of age and older with moderately to severely active Crohn’s disease who have had an inadequate response to conventional therapy
        • reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing Crohn’s disease
        • reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult or pediatric patients 6 years of age and older with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy
        • [in combination with methotrexate] reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active disease
        • reducing signa and symptoms in adult patients with active ankylosing spondylitis
        • reducing signa and symptoms of active psoriatic arthritis, inhibiting the progression of structural damage, and improving physical function in adult patients
        • treatment of adult patients with chronic severe plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate
    • Disease: ankylosing spondylitis, Crohn’s disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis

    • Therapeutic Area: Gastroenterology, Rheumatology, Dermatology

    • Enrollment Form Link: Pfizer enCompass

    • Phone Number: 1-844-722-6672
    • Fax Number: 1-844-722-6672
    • Product Website: inflectra.com

  • Ixifi

    • Drug: Ixifi (infliximab-qbtx)

    • Manufacturer: Pfizer

    • Route of Administration: Intravenous
    • Site of Care: Outpatient
    • Approved Indication:

        • reducing signs and symptoms and inducing and maintaining clinical remission in adults or pediatric patients 6 years of age and older with moderately to severely active Crohn’s disease who have had an inadequate response to conventional therapy
        • reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing Crohn’s disease
        • reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult or pediatric patients 6 years of age and older with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy
        • [in combination with methotrexate] reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active disease
        • reducing signa and symptoms in adult patients with active ankylosing spondylitis
        • reducing signa and symptoms of active psoriatic arthritis, inhibiting the progression of structural damage, and improving physical function in adult patients
        • treatment of adult patients with chronic severe plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate
    • Disease: ankylosing spondylitis, Crohn’s disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis

    • Therapeutic Area: Gastroenterology, Rheumatology, Dermatology

    • Enrollment Form Link: N/A
    • Phone Number: N/A
    • Fax Number: N/A
    • Product Website: www.pfizer/com/ixifi

  • Linzess

    • Drug: Linzess (linaclotide)
    • Manufacturer: AbbVie | Ironwood Pharmaceuticals

    • Route of Administration: Oral

    • Site of Care: Outpatient

    • Approved Indication:

      • treatment of irritable bowel syndrome with constipation in adults
      • treatment of chronic idiopathic constipation in adults
      • treatment of functional constipation in pediatric patients 6 to 17 years of age

    • Disease: irritable bowel syndrome with constipation (IBS-C), chronic idiopathic constipation (CIC), functional constipation

    • Therapeutic Area: Gastroenterology

    • Enrollment Form Link: N/A
    • Phone Number: N/A
    • Fax Number: N/A
    • Product Website: linzess.com

  • Livtencity

    • Drug: Livtencity (maribavir)
    • Manufacturer: Takeda

    • Route of Administration: Oral

    • Site of Care: Outpatient
    • Approved Indication: treatment of adults and pediatric patients (12 years of age and older and weighing at least 35 kg) with post-transplant CMV infection/disease that is refractory to treatment (+/- genotypic resistance) with ganciclovir, valganciclovir, cidofovir, or foscarnet
    • Disease: post-transplant cytomegalovirus (CMV) infection

    • Therapeutic Area: Infectious disease

    • Enrollment Form Link: livtencity.com/access
    • Phone Number: 1-855-268-1825
    • Fax Number: 1-855-268-1826
    • Product Website: livtencity.com

  • lubiprostone

    • Drug: lubiprostone
    • Manufacturer: misc

    • Route of Administration: Oral

    • Site of Care: Outpatient

    • Approved Indication:

      • treatment of irritable bowel syndrome with constipation in women 18 years of age and older
      • treatment of chronic idiopathic constipation in adults
      • treatment of opioid-induced constipation in adult patients with chronic, non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not required frequent opioid dose escalation
    • Disease: irritable bowel syndrome with constipation (IBS-C), chronic idiopathic constipation (CIC), opioid-induced constipation (OIC)

    • Therapeutic Area: Gastroenterology

    • Enrollment Form Link: N/A

    • Phone Number: N/A

    • Fax Number: N/A

    • Product Website: N/A

  • Mavyret

    • Drug: Mavyret (glecaprevir/pibrentasvir)
    • Manufacturer: AbbVie

    • Route of Administration: Oral

    • Site of Care: Outpatient

    • Approved Indication:

      • treatment of adults and pediatric patients 3 years of age and older with chronic HCV genotype 1, 2, 3, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis
      • treatment of adult and pediatric patients 3 years of age and older with HCV genotype 1 infection who previously have been treated with a regimen containing an HCV NS5A or an NS3/4A protease inhibitor, but not both

    • Disease: chronic viral hepatitis C

    • Therapeutic Area: Infectious disease, Gastroenterology, Hepatology
    • Enrollment Form Link: mavyret.com/nurse-ambassador
    • Phone Number: 1-877-MAVYRET (1-877-628-9738)
    • Fax Number: 1-866-938-6696
    • Product Website: mavyret.com

  • Motegrity

    • Drug: Motegrity (prucalopride)
    • Manufacturer: Takeda

    • Route of Administration: Oral

    • Site of Care: Outpatient

    • Approved Indication: treatment of chronic idiopathic constipation in adults
    • Disease: chronic idiopathic constipation (CIC)
    • Therapeutic Area: Gastroenterology
    • Enrollment Form Link: N/A
    • Phone Number: N/A
    • Fax Number: N/A
    • Product Website: motegrity.com

  • Movantik

    • Drug: Movantik (naloxegol)
    • Manufacturer: Valinor Pharma | AstraZeneca

    • Route of Administration: Oral

    • Site of Care: Outpatient
    • Approved Indication: treatment of opioid-induced constipation in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent opioid dosage escalation

    • Disease: opioid-induced constipation (OIC)

    • Therapeutic Area: Gastroenterology

    • Enrollment Form Link: N/A

    • Phone Number: N/A

    • Fax Number: N/A

    • Product Website: movantik.com

  • Myfortic

    • Drug: Myfortic (mycophenolic acid)
    • Manufacturer: Novartis

    • Route of Administration: Oral

    • Site of Care: Outpatient
    • Approved Indication: prophylaxis of organ rejection in adult patients receiving kidney transplants and in pediatric patients at least 5 years of age and older who are at least 6 months post kidney transplant, in combination with other immunosuppressants

    • Disease: solid organ transplant

    • Therapeutic Area: Solid Organ Transplant
    • Enrollment Form Link: www.mycophenolaterems.com

    • Phone Number: N/A

    • Fax Number: N/A
    • Product Website: N/A

  • Ofev

    • Drug: Ofev (nintedanib)
    • Manufacturer: Boehringer Ingelheim

    • Route of Administration: Oral

    • Site of Care: Outpatient
    • Approved Indication:

      • treatment of idiopathic pulmonary fibrosis in adults
      • treatment of chronic fibrosis interstitial lung diseases with a progressive phenotype in adults
      • slowing the rate of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease in adults
    • Disease: idiopathic pulmonary fibrosis (IPF), interstitial lung disease (ILD)

    • Therapeutic Area: Pulmonary

    • Enrollment Form Link: Prescription Form

    • Phone Number: 855-297-5906 (BI Cares)

    • Fax Number: N/A

    • Product Website: ofev.com